Abstract

The potential rewards for biotech licensor companies are now higher than ever, but nothing is certain: the inherent risk of drug development, along with associated costs, regulatory and price issues, could make a drug product non-viable in the end. Is paying more for drugs thus something that we may have to accept, in spite of the considerable political pressure to stop the price of drugs rising?

Copyright: © IQVIA 2018